This idea is supported by evidence from MYC-driven models where inhibition of glycolysis with LDHA inhibitors or inhibitors of the NAD+ salvage enzyme nicotinamide phosphoribosyl-transferase (NAMPT) led to selective toxicity in MYC-overexpressing pancreatic cancer and glioblastoma cells [78,79]. The gene discussed is MYC; the disease is pancreatic neoplasm.